FDA Inspection 1286862 — Aurobindo Pharma Limited
The FDA completed an inspection of Aurobindo Pharma Limited on September 5, 2025 in Medchal. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- September 5, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Medchal (India)